跳至主要内容
临床试验/KCT0006650
KCT0006650尚未招募未知

Cohort study for management of patients with early-onset dementia

Pusan National University Hospital0 个研究点目标入组 400 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
400

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
19?(Year) 至 o Limit(—)
性别
All

入选标准

  • ? Early onset AD
  • ? Onset age between 19-64 years
  • ? Meets DSM-V criteria for Dementia (American Psychiatric Association. 2013)
  • ? Meets NIA-AA criteria for Probable AD dementia (McKhann et al., 2011)
  • ? Amyloid positive status (PET scan) or A+T+N+ status based on CSF AD biomarkers
  • ? Must have a caregiver who can provide information about the participant’s cognitive and functional performance
  • ? Willing and able to consent to the protocol
  • ? Early onset MCI
  • ? Onset age between 19-64 years
  • ? Memory or cognitive functions complaint, preferably corroborated by an informant
  • ? Preserved activities of daily living
  • ? Not demented
  • ? Amyloid positive status (PET scan) or A+T+N+ status based on CSF AD biomarkers
  • ? Must have a caregiver who can provide information about the participant’s cognitive and functional performance
  • ? Willing and able to consent to the protocol
  • ? Early SCD
  • ? Onset age between 19-64 years
  • ? Subjective cognitive impairment
  • ? Meets criteria for cognitively normal, based on neuropsychological test
  • ? Amyloid positive status (PET scan) or A+T+N+ status based on CSF AD biomarkers
  • ? Willing and able to consent to the protocol
  • ? Onset age between 19-64 years
  • ? Meets criteria for bvFTD (Rascovsky et al., 2011)
  • ? Meets criteria for svPPA (Gorno-Tempini et al., 2011)
  • ? Meets criteria for nfvPPA (Gorno-Tempini et al., 2011)
  • ? Meets El Escorial criteria for MND combined with FTD
  • ? Must have a caregiver who can provide information about the participant’s cognitive and functional performance
  • ? Willing and able to consent to the protocol
  • ? Other EOD
  • ? Onset age between 19-64 years
  • ? Leukodystrophy
  • ? Early onset neurodegenerative dementia other than FTD or EOAD
  • ? Other unspecified EOD
  • ? Must have a caregiver who can provide information about the participant’s cognitive and functional performance
  • ? Willing and able to consent to the protocol
  • # Family Members
  • ? Family members whose patient has known pathogenic mutations, two or more first degree family members with EOD, or one or more family member with EOD for 3 generations
  • ? Willing and able to consent to the protocol

排除标准

  • ? History of major psychiatric disorders (schizophrenia, major depression, bipolar disorders, alcohol/substance abuse, delirium, etc.)
  • ? History of cerebral infarction, cerebral hemorrhage, brain tumor or systemic disease which could affect cognitive functions
  • ? Contraindications to MRI or CT (e.g., claustrophobia, pacemaker, select aneurismal clip, metal fragments, or ventriculoperitoneal shunt, etc.)
  • ? Illiteracy
  • ? Previous enrollment in a therapeutic trial
  • ? Pregnant or lactating
  • ? Deemed ineligible by the site PI for any other reason

研究者

相似试验

进行中(未招募)
不适用
A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinomaocally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma.
EUCTR2004-005218-35-SEordic Society of Gynecological Oncology (NSGO)50
已完成
不适用
Observational cohort study in patients with severe asthma based on clinical phenotypesBronchial asthma
JPRN-UMIN000003254Division of Respiratory Medicine, Department of Internal Medicine, Hokkaido University Graduate School of Medicine300
已完成
不适用
Cohort study of patients with initially unresectable pancreatic cancer in whom conversion surgery is planned after FOLFIRINOX or gemcitabine plus nab-paclitaxel therapynresectable pancreatic cancer
JPRN-UMIN000035668Federation of Asian Clinical Oncology (FACO)360
进行中(未招募)
1 期
Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomidePhase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with radiotherapy and concomitant and adjuvant temozolomideMedDRA version: 9.1Level: LLTClassification code 10018336Term: GlioblastomaMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiforme
EUCTR2008-001078-34-NLMaastro Clinic57
招募中
不适用
Phase I/II study for patients with newly diagnosed glioblastoma testing nelfinavir in combination with concomitant temozolomide and radiotherapy.10029211glioblastoma
NL-OMON32210Academisch Ziekenhuis Maastricht58